REG - Intuitive Invests.Gp - Investment in Shield Therapeutics plc

Intuitive InvestmentsAnnouncement

01/03/2021 07:01

RNS Number : 6051Q
  
Intuitive Investments Group plc
  
01 March 2021
  
 

1 March 2021 
Intuitive Investments Group plc
Investment in Shield Therapeutics plc
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £250,000 to acquire 833,333 ordinary shares of Shield Therapeutics plc (AIM: STX) ("Shield") at a price of 30 pence per share (the "Investment"). The Investment is part of Shield's fundraising as announced by Shield on 26 February 2021 (the "Fundraising"). The Investment is conditional upon, amongst other things, each of the resolutions being passed at Shield's forthcoming general meeting.
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. 
Robert Naylor has personally invested £68,600 as part of the Fundraising. Accordingly, Robert Naylor did not vote as a member of the Investment Team of IIG approving the Investment. 
The Investment in is the Company's seventh investment following its IPO in mid-December 2020.
For further information, please contact:



Intuitive Investments Group plc


www.iigplc.com 




David Evans, Executive Chairman
Robert Naylor, CEO


Via Walbrook PR




 


 




Strand Hanson Limited - Nominated Adviser


+44 (0) 20 7409 3494




James Harris / James Dance / James Bellman
 


















 
Turner Pope Investments (TPI) Ltd - Broker


+44 (0) 20 3657 0050




Andrew Thacker / Zoe Alexander


 




 


 




Walbrook PR Limited - Media & Investor Relations


+44 (0)20 7933 8780 or intuitive@walbrookpr.com




Paul McManus


+44 (0) 7980 541 893



 
About Intuitive Investments Group plc
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCGZGZZGRRGMZZ